Capital International Sarl Gracell Biotechnologies Inc. Transaction History

Capital International Sarl

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$2.08 - $3.96 $15,369 - $29,260	-7,389 Reduced 2.43%	297,193 $683,000
Q3 2022 Nov 14, 2022	BUY	$2.08 - $5.15 $4,992 - $12,360	2,400 Added 0.79%	304,582 $981,000
Q2 2022 Aug 15, 2022	BUY	$1.95 - $5.5 $144,364 - $407,181	74,033 Added 32.45%	302,182 $1.66 Million
Q1 2022 May 16, 2022	BUY	$1.83 - $5.52 $15,569 - $46,964	8,508 Added 3.87%	228,149 $532,000
Q4 2021 Feb 14, 2022	BUY	$5.65 - $14.9 $339,847 - $896,235	60,150 Added 37.71%	219,641 $1.33 Million
Q3 2021 Nov 15, 2021	BUY	$9.91 - $14.84 $152,970 - $229,070	15,436 Added 10.72%	159,491 $2.21 Million
Q2 2021 Aug 16, 2021	BUY	$9.75 - $18.42 $105,095 - $198,549	10,779 Added 8.09%	144,055 $1.87 Million
Q1 2021 May 14, 2021	BUY	$14.7 - $30.57 $1.96 Million - $4.07 Million	133,276 New	133,276 $2.05 Million

75.1K

Ticker GRCL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,674,096
Description
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the tre...

Get notified when there are updates to the investment portfolio of Capital International Sarl, based on Form 13F filings with the SEC.

Stay updated on Capital International Sarl with notifications on news.